AIN457 provided fast and significant comfort of symptoms in up to 81 percent of sufferers with psoriasis Novartis has announced positive results from three Phase II trials showing that AIN457 produced an instant and significant improvement of symptoms in patients with moderate-to-severe plaque psoriasis. The results were presented at the annual European Academy of Dermatology and Venereology Congress, in Lisbon, Portugal. In a single study, 81 percent of patients receiving AIN457 150mg subcutaneously monthly experienced at least a 75 percent improvement of psoriasis signs or symptoms as measured by PASI vs 9 percent for placebo at week 12 (p.The I-SPY 2 trial, which will enroll patients at 20 leading U.S. Cancers research centers, will also depend on Agendia’s TargetPrint to supply objective, quantitative information about the expression of the precise tumor-related proteins, ER, PR and Her-2neu, while Agendia’s DiscoverPrint will measure the expression of the complete genome for all enrolled sufferers. These tests allow the study researchers to quicker identify which investigational medicines offer the most benefit for females with certain tumor characteristics. The new Irvine facility consists of corporate offices and a 15,000 square foot, state-of-the-artwork genomics laboratory. A large group of California politicians and other VIPs attended the inauguration, like the Mayor of Irvine, Sukhee Kang, and representatives of individual clinicians and organizations.